RTTNews | Nov 13, 2020 10:24PM EST

22:24 Friday, November 13, 2020 (RTTNews.com) - Agilent Technologies Inc. (A) said that it has received FDA approval for the use of PD-L1 IHC 22C3 pharmDx as an aid in identifying patients with triple-negative breast cancer for treatment with KEYTRUDA or pembrolizumab.

The announcement marked the seventh cancer type for which PD-L1 IHC 22C3 pharmDx has gained approval in the U.S.

PD-L1 expression is a critical biomarker for response to anti-PD-1 therapies such as KEYTRUDA. The expanded use of PD-L1 IHC 22C3 pharmDx strengthens the ability of pathologists to identify patients who may be eligible for treatment with KEYTRUDA, the company said in a statement.

KEYTRUDA, in combination with chemotherapy, is approved for patients with locally recurrent unresectable or metastatic triple-negative breast cancer whose tumors express PD-L1 as determined by an FDA-approved test.

Read the original article on RTTNews ( https://www.rttnews.com/3146103/agilent-obtains-expanded-fda-approval-for-pd-l1-ihc-22c3-pharmdx-in-triple-negative-breast-cancer.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2020 RTTNews.com All Rights Reserved